Valuation: XOMA Royalty Corporation

Market Cap 562M 491M 453M 419M 796M 53.63B 809M 5.43B 2.13B 26.34B 2.11B 2.06B 91.22B P/E 2026 *
56.9x
P/E 2027 * -896x
Enterprise Value 562M 491M 453M 419M 796M 53.63B 809M 5.43B 2.13B 26.34B 2.11B 2.06B 91.22B EV / Sales 2026 *
9.25x
EV / Sales 2027 * 10.7x
Free-Float
97.66%
Yield 2026 *
-
Yield 2027 * -
1 day-0.44%
1 week+4.19%
Current month+5.41%
1 month+6.79%
3 months+21.87%
6 months+50.08%
Current year+68.48%
1 week 42.9
Extreme 42.905
45.22
1 month 40.76
Extreme 40.76
45.22
Current year 22.29
Extreme 22.29
45.22
1 year 22.29
Extreme 22.29
45.22
3 years 13.48
Extreme 13.48
45.22
5 years 13.48
Extreme 13.48
45.22
10 years 3.96
Extreme 3.96
46.32
Manager TitleAgeSince
Chief Executive Officer 51 2022-12-31
Director of Finance/CFO 42 2026-01-11
Chief Investment Officer 45 2023-01-02
Director TitleAgeSince
Director/Board Member 60 2021-08-05
Chairman 70 2024-01-06
Director/Board Member 72 2012-12-12
Date Insider Type Main position Quantity % Market Cap.
05-20Other

Director

0 0%
05-20Other

Director

0 0%
05-20Free

Director

3,586 0.0296%
Change 5-day change 1-year change 3-year change Capi.($)
-0.44%+4.19%+61.67%+168.42% 562M
+0.43%-2.94%+41.28%+63.83% 558M
+0.71%-0.35%-8.44%-15.82% 360M
+1.93%+1.06%-27.53%-34.65% 84.05M
Average +0.66%+0.23%+16.75%+45.45% 390.88M
Weighted average by Cap. +0.26%+0.49%+33.48%+77.81%

Financials

2026 *2027 *
Net sales 60.73M 53.13M 48.99M 45.33M 86.04M 5.8B 87.48M 587M 230M 2.85B 228M 223M 9.86B 52.5M 45.93M 42.35M 39.19M 74.38M 5.01B 75.62M 507M 199M 2.46B 197M 193M 8.52B
Net income 15.03M 13.15M 12.13M 11.22M 21.3M 1.43B 21.65M 145M 56.93M 705M 56.44M 55.22M 2.44B -900K -787K -726K -672K -1.28M -85.91M -1.3M -8.69M -3.41M -42.19M -3.38M -3.31M -146M
Net Debt - -
Logo XOMA Royalty Corporation
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
Employees
14
Date Price Change Volume
26-07-09 US$44.80 -0.44% 375,675
26-07-08 US$45.00 +2.53% 255,335
26-07-07 US$43.89 +0.09% 144,744
26-07-06 US$43.85 +1.98% 209,109
26-07-02 US$43.00 +0.89% 137,659
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
44.80USD
Average target price
39.00USD
Spread / Average Target
-12.95%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. XOMA Stock